Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A biocompatible composition comprising a polymer particle having a therapeutic agent~~, a polymer~~ and a buoyancy agent contained therein, wherein the buoyancy agent is a gas or oil and wherein the composition is controllably buoyant within the cerebrospinal fluid.

2. (Original) The composition of claim 1, wherein the polymer is biodegradable.

3. (Cancelled).

4. (Original) The composition of claim 1, wherein said buoyancy agent has a specific gravity of between about 1.0063 to about 1.0075.

5. (Original) The composition of claim 1, wherein said buoyancy agent has a specific gravity greater than about 1.0063

6. (Original) The composition of claim 1, wherein said buoyancy agent has a specific gravity less than about 1.0063

7. (Original) The composition of claim 1, wherein said therapeutic agent is a neuroprotective agent and said composition is administered to a subject having a central nervous system disorder.

8. (Original) The composition of claim 1, wherein said buoyancy agent is a mixture of oxygen and nitrogen.

9. (Original) The composition of claim 1, wherein said buoyancy agent is a hydrofluorocarbon.

10. (Original) The composition of claim1, wherein said buoyancy agent is a gas selected from the group consisting of nitrogen, argon, carbon dioxide, helium, and xenon.

11. (Currently amended) The composition of claim 1, wherein said therapeutic agent is selected from the group consisting of inosine, citicholine, superoxide dismutase (SOD), and dextrorphan.

12. (Currently amended) A composition comprising a first polymeric particle having a ~~comprising a~~ first therapeutic agent and a buoyancy agent contained therein, and a second polymeric particle comprising a second therapeutic agent~~, wherein said first and said second polymeric particles comprise~~ and a buoyancy agent contained therein, wherein the buoyancy agents are selected from gases and oils, further wherein the composition is controllably buoyant within the cerebrospinal fluid.

13. (Currently amended) The composition of claim 12, wherein ~~said~~the ratio of said first polymeric particle and said second polymeric particle is 50:50.

14. (Currently amended) The composition of claim 12, wherein ~~said~~the ratio of said first polymeric particle and said second polymeric particle is 60:40.

15. (Currently amended) The composition of claim 12, wherein ~~said~~the ratio of said first polymeric particle and said second polymeric particle is 40:60.

16. (Currently amended) The composition of claim 2, wherein said biodegradable polymer is a naturally derived polymer selected from the group consisting of albumin, alginate, cellulose ~~derivatives~~, collagen, fibrin, gelatin, and polysaccharides.

17. (Currently amended) The composition of claim 2, wherein said biodegradable polymer is a synthetic polymer selected from the group consisting of polyesters, polyethylene glycol, poloxomers, polyanhydrides, polyamides, polyurethanes, and pluronics.

18. (Original) The composition of claim 17, wherein said synthetic polymer is poly(lactide-co-glycolide).

19. (Currently amended) The composition of claim 1, wherein said therapeutic agent is selected from the group consisting of L-dopa, dopamine, carbidopa, choline, acetylcholine, cholinergic neuronotropic agents, gangliosides, nerve growth enhancing agents, living cells ~~such as bone marrow cells or fetal neural tissue or stem cells~~, enzymes, antipsychotropic agents, antidepressants, excitatory amino acid antagonist or agonist, antiepileptic ~~medications~~medications, ~~enzymes~~ and combinations thereof as well as antioxidants, nonsteroidal anti-inflammatory drugs (NSAIDS), steroidal anti-inflammatory agents, calcium channel blockers, N-methyl-D-aspartate (NMDA) antagonists, inosine, citicholine, superoxide dismutase ~~SOD~~, dextrorphan, aspirin, and tetramethylpyrazine.

20. (Currently amended) The composition of claim 1, wherein said therapeutic agent is a cancer agent selected from the group consisting of vinca alkaloids and other plant products, cytostatic drugs, cytotoxic drugs, hormones ~~(estrogens and anti-estrogens)~~, alkylating agents,

immunomodulators ~~(immunostimulators and immunosuppressives)~~, hematological agents, ~~non-steroidal products,~~ radiopharmaceuticals, antibodies, antiandrogens, and epidermals.

21. (Currently amended) The composition of claim 7, wherein said central nervous system disorder is selected from the group consisting of cancer, Parkinson's disease, Alzheimer's dementia, Huntington's disease, epilepsy, amyotrophic lateral sclerosis~~ALS~~, multiple sclerosis~~MS~~, ~~antibiotic delivery,~~ trauma, stroke, traumatic brain injury~~TBI~~, depression, spinal cord injury, and pain management ~~and other types of neurological and psychiatric illnesses~~.

22. (Currently amended) A method for administering a therapeutic agent within the central nervous system of a subject, the method comprising intrathecally administering a composition to ~~contacting a~~ the central nervous system of said subject, ~~tissue with~~ wherein said composition comprises a biodegradable polymer particle having ~~composition comprising~~ a therapeutic agent[[,]] ~~a polymer~~ and a buoyancy agent contained therein, wherein the buoyancy agent is a gas or an oil, and wherein the composition is controllably buoyant within the cerebrospinal fluid.

23. (Original) The method of claim 22, wherein said subject is diagnosed with a central nervous system disorder.

24. (Original) The method of claim 23, wherein said composition is in the form of a plurality of spherical particles from about 1 to about 25 μm in diameter.

25. (Currently amended) The method of claim 23, wherein the therapeutic agent is selected from the group consisting of L-dopa, dopamine, carbidopa, choline, acetyl choline, cholinergic neuronotropic agents, gangliosides, nerve growth enhancing agents, living cells ~~such as bone marrow cells or fetal neural tissue or stem cells~~, enzymes, antipsychotropic agents, antidepressants, excitatory amino acid antagonist or agonist, antiepileptic ~~medications~~medications,~~enzymes~~ and combinations thereof as well as antioxidants, nonsteroidal

anti-inflammatory drugs (NSAIDS), steroidal anti-inflammatory agents, calcium channel blockers, N-methyl-D-aspartate (NMDA) antagonists, inosine, citicholine, superoxide dismutase~~SOD~~, dextrorphan, aspirin, and tetramethylpyrazine.

26. (Currently amended) The method of claim 23 wherein the therapeutic agent is a cancer agent selected from the group consisting of vinca alkaloids and other plant products, cytostatic drugs, cytotoxic drugs, hormones ~~(estrogens and anti-estrogens)~~, alkylating agents, immunomodulators ~~(immunostimulators and immunosuppressives)~~, hematological agents, ~~non-steroidal products,~~ radiopharmaceuticals, antibodies, antiandrogens, and epidermals.

27. (Currently amended) The method of claim 23, wherein the ~~contacting a central nervous system tissue is by~~ intrathecal administration occurs directly into the cerebrospinal fluid of the subject.

28. (Currently amended) The method of claim 23, wherein the central nervous system disorder is selected from the group consisting of cancer, Parkinson's disease, Alzheimer's dementia, Huntington's disease, epilepsy, amyotrophic lateral sclerosis~~ALS~~, multiple sclerosis~~MS~~, ~~antibiotic delivery,~~ trauma, stroke, traumatic brain injury~~TBI~~, depression, spinal cord injury, and pain management ~~and other types of neurological and psychiatric illnesses~~.

29. (Currently amended) The method of claim 23, wherein said biodegradable polymer is a naturally derived polymer selected from the group consisting of albumin, alginate, cellulose ~~derivatives~~, collagen, fibrin, gelatin, and polysaccharides.

30. (Original) The method of claim 23, wherein said biodegradable polymer is a synthetic polymer selected from the group consisting of polyesters, polyethylene glycol, poloxomers, polyanhydrides, and pluronics.

31. (Original) The method of claim 23, wherein said synthetic polymer is poly(lactide-co-glycolide).

32. (Original) The composition of claim 12, wherein said first therapeutic agent is inosine and said second therapeutic agent is citicholine.

33. (Currently amended) The composition of claim 1, ~~wherein~~wherein said buoyancy agent is selected from the group consisting of fish oil, vegetable oil, and vitamin E oil~~, and PEG~~.

34. (New) The composition of claim 1, wherein said therapeutic agent is an antibiotic and said composition is administered to a subject needing antibiotic treatment.

35. (New) The method of claim 22, wherein said therapeutic agent is an antibiotic and said subject is in need of antibiotic treatment.

36. (New) The composition of claim 19, wherein said living cells are selected from bone marrow cells and fetal neural tissue or stem cells.

37. (New) The composition of claim 20, wherein said hormones are selected from estrogens and anti-estrogens.

38. (New) The composition of claim 20, wherein said immunomodulators are selected from immunostimulators and immunosuppressives.

39. (New) The method of claim 25, wherein said living cells are selected from bone marrow

cells and fetal neural tissue or stem cells.

40. (New) The method of claim 26 wherein said hormones are selected from estrogens and anti-estrogens.

41. (New) The method of claim 26 wherein said immunomodulators are selected from immunostimulators and immunosuppressives.